CORNEAL DYSTROPHIES

Corneal Dystrophies

Corneal dystrophies are a heterogeneous group of inherited, usually bilateral, non-inflammatory corneal disorders characterized by the accumulation of abnormal material within specific layers of the cornea. These conditions often present in childhood or early adulthood and tend to progress slowly, leading to visual impairment of varying severity. Advances in genetics, imaging, and surgical techniques have significantly improved the diagnosis and management of corneal dystrophies in recent years.

Classification and Genetics

Corneal dystrophies are traditionally classified based on the anatomical layer of the cornea affected: epithelial and subepithelial dystrophies, Bowman layer dystrophies, stromal dystrophies, and endothelial dystrophies. This classification is supported by molecular genetic findings that have clarified disease mechanisms and inheritance patterns.

Most corneal dystrophies are inherited in an autosomal dominant manner, though autosomal recessive and X-linked forms exist. Mutations in genes such as TGFBI, KRT3, KRT12, CHST6, and COL8A2 have been implicated in various dystrophies. Genetic testing has become increasingly important for accurate diagnosis and counseling.

Epithelial and Bowman Layer Dystrophies

Epithelial dystrophies primarily affect the corneal epithelium and its basement membrane. Epithelial basement membrane dystrophy is the most common form and may cause recurrent corneal erosions, leading to pain, photophobia, and blurred vision.

Bowman layer dystrophies, including Reis–Bücklers dystrophy and Thiel–Behnke dystrophy, present with recurrent erosions and progressive corneal opacity. These conditions often manifest in early childhood and can significantly affect visual quality.

Stromal Dystrophies

Stromal dystrophies are characterized by deposits within the corneal stroma. Granular, lattice, and macular corneal dystrophies are among the most well-known stromal dystrophies. Granular and lattice dystrophies are commonly associated with TGFBI mutations and typically present with progressive opacities that impair vision over time.

Macular corneal dystrophy, an autosomal recessive condition, is caused by mutations in the CHST6 gene and leads to diffuse stromal clouding and early visual impairment. Unlike other stromal dystrophies, macular dystrophy often presents at a younger age and progresses more rapidly.

Endothelial Dystrophies

Endothelial dystrophies affect the innermost layer of the cornea and impair fluid regulation, leading to corneal edema. Fuchs endothelial corneal dystrophy (FECD) is the most common endothelial dystrophy and typically presents in middle to late adulthood with blurred vision, glare, and morning visual fluctuations.

Other endothelial dystrophies include congenital hereditary endothelial dystrophy, which presents in infancy with corneal clouding and reduced vision. Advances in endothelial keratoplasty have transformed the management of these conditions.

Diagnosis

Diagnosis of corneal dystrophies relies on a combination of clinical examination, slit-lamp biomicroscopy, corneal imaging, and genetic testing. Modern imaging techniques such as anterior segment optical coherence tomography and in vivo confocal microscopy provide detailed visualization of corneal layers and deposits.

Differentiating corneal dystrophies from degenerations and secondary corneal diseases is essential for appropriate management.

Management and Treatment

Management depends on the type and severity of the dystrophy. Mild cases may be managed conservatively with lubrication, hypertonic saline, and management of recurrent erosions. Advanced disease with significant visual impairment often requires surgical intervention.

Surgical options include phototherapeutic keratectomy (PTK) for superficial dystrophies and lamellar or penetrating keratoplasty for deeper stromal involvement. Endothelial dystrophies are increasingly treated with Descemet membrane endothelial keratoplasty (DMEK) or Descemet stripping endothelial keratoplasty (DSEK), which offer faster visual recovery and better outcomes.

Prognosis and Future Directions

The prognosis of corneal dystrophies varies widely depending on the specific condition and available treatment. Recurrence of dystrophy after corneal transplantation remains a challenge in some forms. Ongoing research into gene therapy, targeted molecular treatments, and tissue engineering holds promise for more definitive therapies in the future.

Conclusion

Corneal dystrophies represent a diverse group of inherited corneal disorders with significant visual consequences. Advances in genetics, imaging, and surgical techniques have improved diagnostic precision and patient outcomes. Early recognition, accurate classification, and individualized management are essential for preserving vision and improving quality of life in affected individuals.